DSGN vs MYI Comparison

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.

BLACKROCK MUNIYIELD QUALITY FUND III, INC. is an investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes, as is consistent with its investment policies and prudent investment management. The fund invests a majority of its assets in municipal obligations exempt from U.S. federal income taxes (except that the interest may be subject to the U.S. federal alternative minimum tax). Under normal market conditions, the fund invests mainly in long-term municipal obligations that are investment-grade quality or are considered by the adviser to be of comparable quality at the time of investment. It can also invest directly in such securities or synthetically through the use of derivatives.